Last updated: 02/14/2024 04:00:32
Meta-Analysis Plan for DB2114417 and DB2114418: Exercise endurance studies to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719 (umeclidinium)/GW642444 (vilanterol).
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Meta-Analysis Plan for DB2114417 and DB2114418: Exercise endurance studies to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719 (umeclidinium)/GW642444 (vilanterol).
Trial description: Meta-Analysis Plan for DB2114417 and DB2114418: Exercise endurance studies to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719 (umeclidinium)/GW642444 (vilanterol).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2016-26-01
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Balouri M, Locantore N, Riley JH. Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:203-215
DOI: 10.2147/COPD.S145285
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
umeclidinium bromide, umeclidinium bromide/vilanterol, vilanterol
Collaborators
Not applicable
Study date(s)
January 2015 to January 2016
Type
Observational
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2016-26-01
Actual study completion date
2016-26-01
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website